FDA Category 2 Peptides and 503A Compounding: What Clinics and Peptide Brands Can Still Offer

The peptide compounding landscape changed substantially in 2026. FDA continues to evaluate bulk drug substances for potential use under section 503A, while several peptides previously associated with Category 2 moved through nomination withdrawals and Pharmacy Compounding Advisory Committee review.

For clinics and peptide brands, the practical issue is understanding what 503A permits, how 503B differs, and how product status affects marketing claims. Peptide marketing agencies familiar with regulated markets can support SEO, content, first-party audience development, eligible paid media, and retention without relying on unsupported therapeutic messaging.

Key Takeaways

• Category 1 is not FDA approval: It covers certain nominated bulk substances under an interim enforcement policy when applicable conditions are met
• Category 2 identifies significant safety concerns: FDA does not extend its Category 1 enforcement policy to these substances
• BPC-157, KPV, TB-500, and MOTS-c changed status in 2026: Earlier nominations were withdrawn, while related forms moved through PCAC review
• PCAC recommendations do not automatically authorize compounding: The advisory process is only one step in FDA's evaluation
• 503A and 503B operate differently: 503A generally centers on patient-specific prescriptions, while 503B outsourcing facilities can produce qualifying office stock
• Owned channels matter for peptide marketing: SEO, educational content, first-party data, and email give brands alternatives when paid-media eligibility is limited

Understanding FDA Category 2 Peptides

FDA's Category 1, Category 2, and Category 3 system is part of an interim policy for certain bulk drug substances nominated for the 503A Bulks List.

Under the FDA's current 503A bulk-substance framework:

• Category 1: Substances under evaluation that may fall within FDA's interim enforcement policy when its conditions are satisfied
• Category 2: Substances for which FDA has identified significant safety concerns
• Category 3: Substances nominated without enough supporting information for FDA to evaluate them

These categories do not represent drug approval. Category 1 also does not create blanket permission to compound a substance without satisfying the other requirements of section 503A.

What Changed for BPC-157, KPV, TB-500, and MOTS-c

BPC-157, KPV, TB-500, and MOTS-c illustrate why peptide status cannot be reduced to a simple Category 1 or Category 2 label.

FDA's April 2026 update removed several earlier nominations from Category 2 after those nominations were withdrawn. FDA subsequently considered related free-base and acetate forms for potential inclusion on the 503A Bulks List.

At the July 23 and 24, 2026 PCAC meeting, FDA brought BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide-related substances before the advisory committee.

PCAC review is part of the evaluation process. It does not itself add a substance to the 503A Bulks List.

Category 1 Is an Interim Enforcement Policy

A substance appearing in Category 1 may fall within FDA's interim enforcement discretion while the agency evaluates whether it belongs on the 503A Bulks List.

That distinction matters because a compounded drug does not become FDA-approved simply because its bulk ingredient appears in Category 1.

Compounding also remains subject to the other requirements governing the pharmacy, prescriber, prescription, ingredients, and formulation involved.

503A Compounding: What the Framework Requires

Section 503A covers qualifying traditional compounding by state-licensed pharmacies, federal facilities, and licensed physicians.

In general, 503A compounding is tied to an identified individual patient and a valid prescription. Limited anticipatory compounding can occur under specific statutory conditions.

For bulk substances, one of the applicable pathways generally must be satisfied. The substance may:

• Comply with an applicable USP or NF monograph
• Be a component of an FDA-approved drug when no applicable monograph exists
• Appear on the 503A Bulks List where the statutory conditions apply
• Fall within an applicable FDA interim enforcement policy while under evaluation

FDA also requires qualifying bulk substances to have a valid certificate of analysis and come from an appropriately registered establishment.

What This Means for Peptide Clinics

A clinic cannot use an online Category 1 list as a complete formulary.

Compounding eligibility depends on the specific ingredient, formulation, prescription, pharmacy, source, and applicable federal and state requirements.

Compounded drugs are also different from FDA-approved drugs. They generally do not undergo the same FDA premarket review for safety, effectiveness, and manufacturing quality.

For clinics, accurate descriptions of compounded products and their regulatory status are therefore central to both clinical operations and marketing.

Research-Use Peptides Are Not a Marketing Loophole

"Research use only" language does not override marketing that shows a product is actually intended for human use.

In an August 2026 FDA warning letter involving peptide products, FDA cited website content as evidence that products labeled for research use were intended as human drugs.

Product descriptions, health claims, instructions, companion products, testimonials, and other marketing context can all contribute to intended-use determinations.

For peptide brands, the practical lesson is straightforward: the product positioning, website copy, and actual intended use need to align.

Product Quality and Compounding Controls

Ingredient quality and sourcing are central to compounded products, particularly sterile injectables.

Operational controls can include:

• Pharmacy license verification
• Documentation supporting use of each bulk substance
• Certificates of analysis
• Sterile-compounding procedures
• Lot-level traceability
• Supplier qualification
• Recall monitoring
• Review of relevant FDA inspection and enforcement history

Accreditation can provide additional information about pharmacy practices, but it does not replace federal or state requirements.

Distinguishing Peptides From Anabolic Steroids

Peptides and anabolic steroids are different classes of substances.

Peptides are chains of amino acids that can interact with biological pathways depending on the molecule. Anabolic steroids are synthetic derivatives of testosterone and are generally regulated as Schedule III controlled substances under federal law.

For marketers, the key issue is avoiding comparisons that imply unsupported muscle-growth, anti-aging, performance, or therapeutic outcomes.

Educational content can explain how a peptide works or how it is regulated without turning that explanation into a treatment claim.

For brands building organic visibility, peptide SEO strategies can address these informational searches while maintaining careful claim language.

Marketing Compliantly in the Peptide Space

Peptide marketing sits at the intersection of drug regulation, healthcare advertising rules, state requirements, and platform policies.

The strongest approach starts with accurate product classification and substantiated messaging.

Marketing Priorities for Peptide Clinics and Brands

• Educational content: Explain product status, mechanisms, sourcing, and processes without unsupported therapeutic promises
• SEO: Build visibility around informational and high-intent searches
• First-party audience development: Create direct communication channels through consent-based acquisition
• Email retention: Maintain relationships through owned channels
• Claim review: Remove unsupported cure, treatment, prevention, or guaranteed-outcome language
• Eligible paid media: Use channels that fit the product, business model, geography, and current platform requirements

Compliance-aware advertising strategies can help coordinate creative, landing pages, claims, targeting, and channel eligibility before campaigns launch.

Marketing should also distinguish clearly between FDA-approved products, compounded drugs, substances still under FDA evaluation, and products genuinely intended only for research.

The Role of First-Party Data for Peptide Brands

First-party data gives peptide brands a direct relationship with their audiences.

Useful first-party channels include:

• Consent-based email subscriptions
• Educational newsletters
• Appointment or consultation requests
• Customer preference centers
• Purchase and engagement data collected with appropriate permissions
• Lifecycle and retention campaigns

High-intent email collection can turn qualified website interest into an ongoing audience relationship.

This becomes particularly valuable when advertising eligibility varies by product, claim, geography, or platform.

503A vs. 503B Compounding

503A pharmacies and 503B outsourcing facilities operate under different federal frameworks.

503A Traditional Compounding

Section 503A generally involves:

• Patient-specific prescriptions
• State pharmacy or professional oversight
• Specific conditions governing bulk substances
• Restrictions involving essentially copies of commercially available drugs
• Interstate distribution requirements
• Exemptions from certain FDA provisions when all statutory conditions are satisfied

503B Outsourcing Facilities

A 503B outsourcing facility:

• Registers with FDA
• Is subject to current good manufacturing practice requirements
• Undergoes FDA inspection
• Must meet adverse-event and other reporting obligations
• Can compound qualifying drugs without first receiving individual patient prescriptions
• Can supply qualifying office stock to healthcare facilities

The FDA's 503A and 503B comparison shows how requirements differ across traditional compounding and outsourcing facilities.

503B status does not make every bulk substance eligible for use. Separate rules still determine which bulk ingredients and products qualify.

GLP-1 Compounding in 2026

Semaglutide and tirzepatide show why shortage-based compounding rules need current verification.

FDA determined that the shortages of tirzepatide and semaglutide injection products were resolved, and the temporary enforcement-discretion periods associated with those shortages have ended.

Under 503A, restrictions remain on regularly compounding products that are essentially copies of commercially available drugs. Patient-specific differences can matter under the statute, but shortage resolution removed the broad shortage-based pathway that had supported higher levels of compounding.

For 503B outsourcing facilities, semaglutide and tirzepatide do not currently appear on the 503B Bulks List or FDA's Drug Shortages List.

FDA's current GLP-1 compounding policy provides the relevant federal framework as supply conditions and enforcement policies change.

Building a Compliant Peptide Business for the Long Term

Peptide businesses benefit from treating regulatory monitoring as part of ongoing operations.

Core areas include:

• Product and bulk-substance inventory
• Documentation supporting each formulation
• Pharmacy and manufacturing relationships
• FDA Category 1 and Category 2 changes
• 503A Bulks List activity
• PCAC meetings and FDA rulemaking
• Drug shortage status
• Marketing claims
• State pharmacy and professional requirements

The same discipline strengthens marketing because it gives content and acquisition teams a clearer framework for what can be promoted and how products should be described.

How Herb Agency Supports Peptide Marketing

Herb Agency brings regulated-market growth experience to peptide brands working in claim-sensitive and restriction-heavy environments.

Its approach connects several parts of the customer journey:

• Search visibility: SEO and educational content can capture high-intent searches around peptide categories, services, and customer questions
• First-party audience development: Consent-based audience growth creates direct communication channels beyond paid platforms
• Content strategy: Educational content can explain complex products and categories with more disciplined claims
• Eligible paid media: Campaign planning can account for product type, audience, geography, landing-page content, and platform eligibility
• Email and retention: Owned communication channels support continued engagement after initial acquisition
• Analytics and measurement: Performance data can connect acquisition, content, audience development, and retention activity

Herb Agency's broader regulated-market experience supports a full-funnel approach for peptide brands that need growth strategies built around accurate messaging and diversified acquisition channels.

By connecting SEO, content, first-party audiences, eligible media, retention, and measurement, Herb Agency gives peptide brands a structured system for building visibility and ongoing customer relationships.

Frequently Asked Questions

Does FDA Category 1 mean a substance is legal to compound?

Category 1 is not FDA approval or blanket authorization. It identifies certain nominated bulk substances that can fall within FDA's interim enforcement policy while they are evaluated for the 503A Bulks List, provided the applicable conditions are satisfied.

What is the current status of BPC-157, KPV, TB-500, and MOTS-c?

Earlier nominations involving these substances were withdrawn from Category 2, while related free-base and acetate forms were considered at the July 2026 PCAC meeting for potential inclusion on the 503A Bulks List. PCAC review does not itself add a substance to that list.

What is the main difference between 503A and 503B compounding?

503A generally centers on patient-specific compounding by qualifying pharmacies or physicians. 503B outsourcing facilities can compound qualifying products without first receiving individual patient prescriptions and can supply office stock, but they are subject to FDA registration, CGMP requirements, inspections, reporting obligations, and additional statutory conditions.

Can semaglutide and tirzepatide still be compounded?

The broad shortage-based pathway has ended because FDA determined the relevant shortages were resolved. Compounding now depends on the normal requirements of sections 503A or 503B, including restrictions involving essentially copies of commercially available or approved drugs and rules governing bulk substances.

How can peptide brands market while regulations continue to change?

Peptide brands can build around educational content, SEO, first-party audiences, email marketing, eligible paid media, and accurate product-status messaging. Marketing works best when product claims, regulatory status, landing pages, and acquisition channels are reviewed as part of the same strategy.

Schedule a call with us to learn more about our services.

Learn more